ANA, New Jersey-based pharmaceutical company ANA Pharma Group, a publicly traded company based in New York City, has raised $30 million from the Wall Street firm Wunderlich Investment Partners.

ANA CEO Paul Efron announced the investment Tuesday.

The firm also announced that it is planning to issue shares of its common stock in the first quarter of 2018.

The company has been growing its sales through acquisitions and strategic acquisitions.

ANAP Pharmaceuticals shares have been trading at $40.66 in early trade on Tuesday.

ANAS has been on a roller coaster ride in recent months.

On Dec. 15, the company filed for bankruptcy protection and it filed for Chapter 11 bankruptcy protection on Feb. 25.

It said the company had $4 billion in cash on hand at the end of the second quarter.

It has also filed for a series of Chapter 11 reorganizations in recent years.

Last week, ANA said it had completed its acquisition of Pfizer.

The deal valued the company at $14.2 billion.

It plans to invest $1 billion in the pharmaceutical company.

ANAA also said it has received funding from private equity firms including Kleiner Perkins Caufield & Byers, the Carlyle Group, the Sater Group, and other private equity funds.

The company had been working with Pfizer on its drug approvals, including a recent drug approval for a cholesterol medication.

The new Pfizer approval comes on the heels of another approval from the FDA for an antipsychotic.

ANAD had already been approved by the FDA last month for its antipsychotics, but it was not clear when the drug approval would be final.

The ANA deal with Pfizell was first reported by Reuters.